US 12,390,449 B2
Substituted 2-aminobenzimidazoles analogs as antibiofilm agents
John Gunn, Columbus, OH (US); Laura Kuo, Columbus, OH (US); Christian Melander, Raleigh, NC (US); and William M. Huggins, Raleigh, NC (US)
Assigned to Ohio State Innovation Foundation, Columbus, OH (US); and North Carolina State University, Raleigh, NC (US)
Filed by Ohio State Innovation Foundation, Columbus, OH (US); and North Carolina State University, Raleigh, NC (US)
Filed on Dec. 19, 2023, as Appl. No. 18/545,458.
Application 17/841,938 is a division of application No. 17/044,517, abandoned, previously published as PCT/US2019/025683, filed on Apr. 3, 2019.
Application 18/545,458 is a continuation of application No. 17/841,938, filed on Jun. 16, 2022, granted, now 11,883,384.
Claims priority of provisional application 62/651,829, filed on Apr. 3, 2018.
Prior Publication US 2024/0156788 A1, May 16, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4184 (2006.01)
CPC A61K 31/4184 (2013.01) 20 Claims
 
1. A method for inhibiting biofilm formation or dispersing a biofilm in a subject comprising the step of administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound having a structure represented by a formula:

OG Complex Work Unit Chemistry
wherein R1 is a structure represented by a formula:

OG Complex Work Unit Chemistry
wherein each of R10a, R10b, R10c, R10d, and R10e is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 haloalkyl, provided that at least one of R10a, R10b, R10c, R10d, and R10e is not hydrogen; and
n is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12,
or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier.